Articles from Zoetis Inc.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2024 financial results and respond to questions from financial analysts during the call.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 21, 2025.

Zoetis Inc. (NYSEZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET.

Zoetis Inc. (NYSEZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world’s leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company’s long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities.

Zoetis Inc. (NYSEZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT.

Zoetis Inc. (NYSEZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue and adjusted EPS.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company’s common stock as of the close of business on Thursday, October 31, 2024.

Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today’s dairy farms through the power of genetics for healthier cows. Combining Danone’s commitment to environmental stewardship with Zoetis’ expertise in animal genetics, the partnership aims to innovate the dairy industry’s approach to breeding for sustainability.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Monday, November 4, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2024 financial results and respond to questions from financial analysts during the call.

Zoetis Inc. (NYSEZTS) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 1:05 p.m. ET.

Zoetis Inc. (NYSEZTS) today reported its financial results for the second quarter of 2024 and raised its guidance for full year 2024.

Zoetis Inc. (NYSEZTS) today announced that its Board of Directors has approved a multi-year $6 billion share repurchase program as part of its capital allocation plans. The demand for Zoetis’ innovative and market-leading portfolio has enabled the company to execute its disciplined capital allocation strategy by reinvesting in growth opportunities and returning capital to shareholders, while delivering long-term value.

Zoetis Inc. (NYSEZTS) will now host its second-quarter 2024 financial results webcast and conference call at 8:00 a.m. (ET) on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 6, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2024 financial results and respond to questions from financial analysts during the call.

As animals and communities continue to face mounting challenges from natural disasters, Zoetis Inc. and the Zoetis Foundation are committed to supporting animal health and community resilience. The Zoetis Foundation brings this commitment to life through grant support to the American Red Cross, which will help provide necessary emergency preparedness and relief to families and communities impacted by disasters. Zoetis Inc. partners with American Humane to increase disaster preparedness and help support the well-being of animals during emergencies.

Zoetis Inc. today published its 2023 Sustainability Report “Advancing Sustainability in Animal Health for a Better Future,” to highlight the company’s progress in achieving its Driven to Care long-term sustainability aspirations and provide continued disclosure on environmental, social and governance (ESG) topics. The report shares Zoetis’ actions to meet aspirations across three pillars: Communities, Animals and Planet. Included in the report is the company’s Sustainability Accounting Standards Board (SASB) and ESG Index, which provides relevant performance indicators, including those identified by SASB for the healthcare – biotechnology and pharmaceuticals industry. This Index also includes Zoetis’ commitment to disclosing progress aligned with the Taskforce on Climate-related Financial Disclosure (TCFD), plus a link to the 2023 CDP Climate Change Questionnaire.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.432 per share for the third quarter of 2024. The dividend will be paid on Wednesday, September 4, 2024, to all holders of record of the Company’s common stock as of the close of business on Thursday, July 18, 2024.

Zoetis Inc. (NYSEZTS) will participate in the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:40 p.m. CT.

Zoetis Inc. (NYSEZTS) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:05 p.m. ET.

Zoetis Inc. (NYSEZTS) has been named to Fair360’s Top 50 Companies list for the first time, underscoring the company’s progress and sustained commitment to advancing Diversity, Equity and Inclusion (DE&I). Zoetis is the only animal health company included in this year’s Top 50 rankings.

Zoetis Inc. (NYSEZTS) today reported its financial results for the first quarter of 2024 and updated its guidance for full year 2024.

Zoetis Inc. (NYSEZTS) and Phibro Animal Health Corporation (Nasdaq: PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.

As we celebrate World Veterinary Day, the Zoetis Foundation is proud to support veterinarians around the world today and everyday by providing grant support to initiatives promoting veterinary education, mental well-being, and livelihoods. Recognizing the invaluable role veterinarians and veterinary technicians play in advancing animal health, the Foundation is committed to helping cultivate a thriving, inclusive veterinary profession.

Zoetis Inc. (NYSEZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call.

Zoetis Inc. (NYSEZTS) will participate in the Barclays Global Healthcare Conference on Thursday, March 14, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:30 a.m. ET.

Zoetis Inc. (NYSEZTS) will participate in the Bank of America Securities 2024 Animal Health Summit on Thursday, February 29, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:40 a.m. ET.

Zoetis Inc. (NYSEZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.432 per share for the second quarter of 2024. The dividend will be paid on Tuesday, June 4, 2024, to all holders of record of the Company’s common stock as of the close of business on Friday, April 19, 2024.

Zoetis Inc. (NYSEZTS) has been selected as a 2024 Catalyst Award recipient for its global initiative, Awareness and Action Drives Impact, that is advancing equity for women and other underrepresented groups across the company — from the frontlines to senior leadership. Zoetis is one of only two organizations receiving this global award and is the first animal health company to be recognized.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 13, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2023 financial results and respond to questions from financial analysts during the call.

Zoetis Inc. (NYSEZTS) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 3:45 p.m. PT.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.432 per share for the first quarter of 2024, an increase of 15% from the quarterly dividend rate paid in 2023. The dividend will be paid on Friday, March 1, 2024, to all holders of record of the Company’s common stock as of the close of business on Friday, January 19, 2024.

Zoetis Inc. (NYSEZTS) will participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 1:00 p.m. ET.

Zoetis Inc. (NYSEZTS) today reported its financial results for the third quarter of 2023 and updated its guidance for full year 2023.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.375 per share for the fourth quarter of 2023. The dividend will be paid on Friday, December 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Wednesday, November 1, 2023.

For the tenth year in a row, Zoetis, the world leader in animal health, has been named one of Seramount’s 100 Best Companies for Working Parents. The recognition reflects Zoetis’ commitment to providing a culture focused on colleagues’ careers, connection and support.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 2, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2023 financial results and respond to questions from financial analysts during the call.

Today, the Zoetis Foundation announced that it will distribute $2.6 million during its second round of 2023 grants, supporting six initiatives to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals.

Zoetis Inc. (NYSEZTS) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:55 p.m. ET.

Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis’ engineering and diagnostics work including device reliability testing. The new building features more than 78,000 square feet including 23,000 square feet of total lab space allotted for a biodevice engineering lab, biodevice science lab, diagnostics engineering lab and diagnostics engineering lab space. Zoetis employs approximately 200 people at its site in Durham, more than half of whom are dedicated to the company’s R&D work.

Zoetis Inc. (NYSEZTS) today reported its financial results for the second quarter of 2023 and updated its guidance for full year 2023.

Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of our new monoclonal antibodies (mAbs) expansion, which will enable the site to increase production of products that control osteoarthritis pain in dogs and cats – our largest growing area of need for pet care customers. The site will also be a home for future innovation and serve as a Veterinary Medicine R&D registration facility for the company.

Zoetis Inc. (NYSEZTS) has been named to Fast Company’s list of Best Workplaces for Innovators for 2023. Zoetis is the only stand-alone animal health company to be included on this year’s list which honors businesses that demonstrate a commitment to encouraging innovation at all levels.

Zoetis Inc. (NYSEZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies. Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call.

Zoetis today published its 2022 Sustainability Report “Together We Are Making a Difference for a Better World”, describing the company’s progress toward achieving its Driven to Care long-term sustainability aspirations and continued disclosure on environmental, social and governance (ESG) topics. The report highlights the company’s journey to advance sustainability in Animal Health for a better future through specific actions that support Communities, Animals and the Planet. These commitments build on Zoetis’ purpose and help achieve the United Nations’ Sustainable Development Goals (SDGs). Included in the report is the company’s ESG Index, which shares key ESG performance indicators, including those identified by the Sustainability Accounting Standards Board (SASB) for the healthcare – biotechnology and pharmaceuticals industry. The Index also includes environmental and social data as well as details on how Zoetis supports the Taskforce on Climate-related Financial Disclosure (TCFD) and its commitment to disclosing progress aligned with TCFD recommendations.

Zoetis Inc. (NYSEZTS) will participate in the Stifel 2023 Jaws and Paws Conference on Wednesday, May 31, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:35 p.m. ET.

Zoetis Inc. (NYSEZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.375 per share for the third quarter of 2023. The dividend will be paid on Friday, September 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Friday, July 21, 2023.

Zoetis Inc. (NYSEZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs. Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life. 1,2

Zoetis Inc. (NYSEZTS) today reported its financial results for the first quarter of 2023 and maintained its guidance for full year 2023.

Zoetis Inc. (NYSEZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team. Zoetis will provide an update on the company’s strategy to deliver long-term profitable growth and value for shareholders, followed by a Q&A session.

Today, the Zoetis Foundation announced that it will distribute $5.3 million during its first round of 2023 grants, supporting 21 initiatives impacting 15 countries to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals, as well as relief efforts for those impacted by the earthquake in Türkiye.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 4, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2023 financial results and respond to questions from financial analysts during the call.

Zoetis Inc. (NYSEZTS) has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2023 World’s Most Ethical Companies. In 2023, 135 honorees were recognized, spanning 19 countries and 46 industries. Zoetis is one of three pharmaceutical companies and the only standalone animal health company included on the list.

Zoetis Inc. (NYSEZTS) will participate in the TD Cowen Health Care Conference on Monday, March 6, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:10 a.m. ET.

Zoetis is pleased to receive a $15.3 million grant from the Bill & Melinda Gates Foundation to further develop and integrate innovative solutions to advance veterinary care and diagnostic services that will ultimately improve livestock health and productivity in Sub-Saharan Africa. The grant will help Zoetis to expand its original African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative to include aquaculture in addition to cattle, poultry, and swine in an additional seven countries in Sub-Saharan Africa. Part of the company’s Driven to Care long-term sustainability commitments, the new five-year African Livestock Productivity and Health Advancement Plus (A.L.P.H.A. Plus) initiative aims to improve veterinary health and food security in some of the most rapidly developing regions in the world.

Zoetis Inc. (NYSEZTS) will participate in the Bank of America Securities 2023 Animal Health Summit on Thursday, March 2, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. ET.

Zoetis Inc. (NYSEZTS) today reported its financial results for the fourth quarter and full year 2022 and provided full year guidance for 2023.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.375 per share for the second quarter of 2023. The dividend will be paid on Thursday, June 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Friday, April 21, 2023.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 14, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2022 financial results and respond to questions from financial analysts during the call.

Zoetis Inc. (NYSEZTS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 1:30 p.m. PT.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.375 per share for the first quarter of 2023, an increase of 15% from the quarterly dividend rate paid in 2022. The dividend will be paid on Wednesday, March 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Friday, January 20, 2023.

Zoetis Inc. (NYSEZTS) will participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022. Glenn David, Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, will represent the company and respond to questions from analysts. He is scheduled to present at 3:30 p.m. ET.

Zoetis Inc. (NYSEZTS) today announced that it has agreed to sell $1.35 billion of senior notes, consisting of $600 million aggregate principal amount of 5.400% senior notes due 2025 and $750 million aggregate principal amount of 5.600% senior notes due 2032, in an underwritten public offering.

Zoetis Inc. (NYSEZTS) today reported its financial results for the third quarter of 2022 and lowered its guidance for full year 2022 to reflect lower than expected sales due to continued supply constraints, veterinary workforce challenges, and the negative impact of recent changes to foreign exchange rates.

The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.325 per share for the fourth quarter of 2022. The dividend will be paid on Thursday, December 1, 2022, to all holders of record of the Company’s common stock as of the close of business on Tuesday, November 1, 2022.

Zoetis has been named to Fortune’s 2022 Change the World list, a global ranking of the top 50 companies making a positive social impact through business practices that are integral to their core corporate purpose. Zoetis’ inclusion on the list is based on the company’s African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, which recently celebrated five years of progress establishing and developing sustainable veterinary care including access to vaccines, medicines and diagnostic services in Sub-Saharan Africa. Zoetis ranked 20th in the list of 50 companies, according to Fortune.

Zoetis Inc. (NYSEZTS) today announced it has completed the acquisition of Jurox, a privately held animal health company that develops, manufactures and markets a wide range of veterinary medicines for treating livestock and companion animals. Jurox’s operations are based in Australia, with additional regional offices in New Zealand, U.S., Canada and the UK. Financial terms of the transaction, which was announced in August 2021, are not being disclosed.

Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 3, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2022 financial results and respond to questions from financial analysts during the call.

For the ninth year in a row, Zoetis has been named one of Seramount’s 100 Best Companies (previously known as the Working Mother 100 Best Companies list).

Zoetis Inc. (NYSEZTS) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:05 p.m. ET.

Zoetis Inc.(NYSEZTS) today reported its financial results for the second quarter of 2022 and updated its guidance for full year 2022 to reflect its positive outlook for the remainder of the year, as well as the negative impact of recent changes to foreign exchange rates.

Zoetis Inc. (NYSEZTS) today announced the appointment of Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs at Johnson & Johnson, to its Board of Directors. Ms. Broadhurst has deep experience in consumer insights and direct-to-consumer advertising, and her appointment increases the size of the Board from 11 to 12 members. She will serve on the Board’s Quality and Innovation Committee.